NOX
Director Trades
| Date | Director | Value |
|---|
Company News
Noxopharm Advances HERACLES Trial as Sofra Platform Gains US Momentum
Noxopharm (ASX: NOX) has successfully completed the second dosing cohort in its first-in-human HERACLES trial for novel autoimmune drug candidate SOF-SKN. The safety steering committee confirmed the dose level was safe and tolerable, enabling the study to progress to a higher concentration in the next cohort. The company also reported promising preclinical results from a […]
Noxopharm advances Chroma drug platform to target glioblastoma and leukaemia
Noxopharm (ASX: NOX) has made ‘substantial progress’ with its Chroma technology platform, reporting encouraging brain cancer results and early work on leukaemia. The Chroma drug development program focuses on generating first-in-class novel cancer treatment options in areas of substantial unmet need to create future commercial opportunities for the company. Glioblastoma – a lethal and incurable […]
Noxopharm reports CRO-67 breakthrough in pancreatic cancer treatment
Australian biotech company Noxopharm (ASX: NOX) has announced encouraging new data regarding the development of its CRO-67 preclinical drug for pancreatic cancer. The results arise from a study that tested CRO-67 in a complex model of human pancreatic cancer cells and barrier cells transplanted into the pancreas of mice. The new data showed a significant […]
Market wrap: ASX 200 closes below 7000-point mark despite a tentative recovery
The Australian share market took a couple of tentative steps in the upwards direction after a tough week in which the ASX 200 fell decisively below the important 7000-point mark. By the Friday close the index had limped upwards 0.4% or 28.7 points to 6,954.2 points after two positive days which followed on from a […]
Noxopharm granted FDA orphan drug status for CRO-67 to treat pancreatic cancer
Australian biotechnology company Noxopharm (ASX: NOX) has been granted orphan drug designation (ODD) status by the US Food and Drug Administration for its CRO-67 preclinical drug candidate to treat pancreatic cancer. The FDA grants the status to drugs designed to prevent, diagnose or treat rare diseases or conditions. It comes with benefits including tax credits […]
Noxopharm’s US biotech subsidiary Nyrada IPO successfully raises $8.5m
Australian biotech Noxopharm’s (ASX: NOX) US spin-off Nyrada Inc (ASX: NYR) experienced strong demand in its initial public offering and will now make its ASX debut today after successfully raising $8.5 million under the ticker ‘NYR’. Nyrada was established by ASX-listed company Noxopharm to advance its non-oncology drug assets. Following the listing, Noxopharm now owns 30.51% […]
Noxopharm’s idronoxil could potentially prevent COVID-19 fatalities, clinical trials to begin
Noxopharm (ASX: NOX) is the latest small cap to reveal it has a potential COVID-19 treatment, after it reported this morning its advanced idronoxil drug could block an excessive inflammatory response believed to be responsible for many COVID-19 fatalities. Branded Veyonda, Noxopharm has already been advancing idronoxil in conjunction with other therapies in clinical trials […]
Noxopharm receives FDA investigational new drug approval for Veyonda
Oncology drug development company Noxopharm (ASX: NOX) has received FDA investigational new drug (IND) approval for using its Veyonda in combination with doxorubicin to treat patients with soft tissue sarcomas. IND allows Noxopharm to go ahead with a phase 1b study involving a combination of Veyonda and doxorubicin in adults. Importantly, the news provides a […]
Noxopharm reports positive interim clinical trial results for cancer drug Veyonda
Biotech company Noxopharm’s (ASX: NOX) came out of a trading halt this morning with positive interim results from its LuPIN phase I/II clinical trial into end-stage prostate cancer. The LuPIN study is currently being conducted by St Vincent’s Hospital in Sydney, where researchers are evaluating Noxopharm’s lead drug candidate, Veyonda, in combination with Lu-PSMA-617, a radiopharmaceutical […]
Noxopharm clinical data shows potential for major new treatment of late-stage prostate cancer
Biotech drug developer Noxopharm (ASX: NOX) has reported positive end-of-study results from its DARRT-1 phase 1b trial treating men with late-stage prostate cancer. In an update yesterday, the oncology-focused company announced that clinical responses had pointed to the NOX66 DARRT treatment regimen as a “potentially major new treatment option”, with two-thirds of study participants having […]
Company Videos
No videos found.